Kailera Therapeutics, Inc. Common Stock (KLRA) - Total Liabilities
Based on the latest financial reports, Kailera Therapeutics, Inc. Common Stock (KLRA) has total liabilities worth $92.95 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See KLRA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Kailera Therapeutics, Inc. Common Stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Kailera Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check Kailera Therapeutics, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Kailera Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Kailera Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tong Yang Industry Co Ltd
TW:1319
|
Taiwan | NT$8.58 Billion |
|
SES S. A.
PA:SESG
|
France | €7.65 Billion |
|
Savaria Corporation
TO:SIS
|
Canada | CA$458.82 Million |
|
Grandjoy Holdings Group Co Ltd
SHE:000031
|
China | CN¥126.11 Billion |
|
Kelt Exploration Ltd.
TO:KEL
|
Canada | CA$477.39 Million |
|
Pegasus Hava Tasimaciligi AS
IS:PGSUS
|
Turkey | TL5.66 Billion |
|
SKYWORTH GRP UNSP.ADR/30
F:KYW0
|
Germany | €53.44 Billion |
|
IBI Inv House
TA:IBI
|
Israel | ILA972.93 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Kailera Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kailera Therapeutics, Inc. Common Stock balance sheet assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kailera Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kailera Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual total liabilities of Kailera Therapeutics, Inc. Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.05 Billion | +164.02% |
| 2024-12-31 | $397.22 Million | -- |
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral … Read more